A device developed by a Georgia Tech biomedical engineering professor that uses artificial intelligence (AI) to improve the treatment process for those with structural heart disease received FDA clearance in June.
Precision TAVI is an (AI)-driven individualized computer predictive modeling tool that can be used to improve patient outcomes, enhanced lifetime planning, and reduced costs associated with treating those needing transcatheter aortic valve replacement.
Lakshmi (Prasad) Dasi, a professor in the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech, is the founder and chief technology officer for Dasi Simulations, the company behind the Precision TAVI.
“DASI Simulations empowers every heart team with critical insights guaranteeing the identification of the best possible care for individual patients, customized to their unique circumstances and anatomy, Dasi said. “One surgery at a time, our technology helps avoid complications, repeated interventions, helps lifelong planning for optimal structural heart care, and has the potential to save billions in unnecessary costs from preventable complications.”
